
Sangamo Therapeutics (SGMO) Stock Forecast & Price Target
Sangamo Therapeutics (SGMO) Analyst Ratings
Bulls say
Sangamo Therapeutics Inc. has significantly enhanced the estimated value of its SIFTER/ZFP platform related to its neurology pipeline, now valued at $7 per share, indicating strong potential for transformational improvements in chronic neuropathic pain treatments. The probability of success for its isa-vec program has increased to 85%, attributed to stronger regulatory positioning, reflecting high investor confidence in the program's viability; however, revenues have been risk-adjusted by 45% due to collaboration terms, maintaining its valuation at $4 per share. Furthermore, the company's commitment to integrating sustainability into its strategy suggests a forward-looking approach, positioning Sangamo for long-term growth while addressing essential stewardship principles within the healthcare ecosystem.
Bears say
Sangamo Therapeutics Inc faces a negative outlook primarily due to its unpredictability in future revenues and expenses, compounded by its non-revenue-generating status, which raises concerns about financial sustainability. The company is currently experiencing significant challenges, including a net loss of $23 million, workforce reductions, and the pausing of late-stage pipeline projects, highlighting operational and financial distress. Additionally, risks related to clinical execution, regulatory uncertainties, and competitive pressures further exacerbate uncertainties regarding the potential for recovery and growth in the company's financial performance.
This aggregate rating is based on analysts' research of Sangamo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sangamo Therapeutics (SGMO) Analyst Forecast & Price Prediction
Start investing in Sangamo Therapeutics (SGMO)
Order type
Buy in
Order amount
Est. shares
0 shares